M&T Bank Corp decreased its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC – Free Report) by 15.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 8,638 shares of the company’s stock after selling 1,555 shares during the period. M&T Bank Corp’s holdings in Henry Schein were worth $591,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also bought and sold shares of HSIC. Palestra Capital Management LLC bought a new stake in shares of Henry Schein in the fourth quarter valued at $182,988,000. Lyrical Asset Management LP bought a new position in Henry Schein in the 4th quarter worth about $126,655,000. Norges Bank bought a new position in Henry Schein in the 4th quarter worth about $103,301,000. Steadfast Capital Management LP raised its holdings in shares of Henry Schein by 254.2% during the 4th quarter. Steadfast Capital Management LP now owns 1,637,808 shares of the company’s stock valued at $113,336,000 after buying an additional 1,175,408 shares in the last quarter. Finally, Hudson Bay Capital Management LP boosted its stake in Henry Schein by 102.1% in the fourth quarter. Hudson Bay Capital Management LP now owns 1,465,007 shares of the company’s stock worth $101,378,000 after buying an additional 740,007 shares in the last quarter. Hedge funds and other institutional investors own 96.62% of the company’s stock.
Henry Schein Stock Performance
NASDAQ:HSIC opened at $70.64 on Wednesday. The stock has a 50-day simple moving average of $71.73 and a two-hundred day simple moving average of $71.33. Henry Schein, Inc. has a 52-week low of $60.56 and a 52-week high of $82.49. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.75 and a current ratio of 1.38. The firm has a market capitalization of $8.60 billion, a PE ratio of 22.08, a P/E/G ratio of 2.28 and a beta of 0.87.
Wall Street Analysts Forecast Growth
Several equities research analysts recently weighed in on the company. Barrington Research dropped their target price on Henry Schein from $90.00 to $86.00 and set an “outperform” rating for the company in a report on Tuesday, May 6th. Robert W. Baird restated a “neutral” rating and issued a $72.00 target price (down previously from $82.00) on shares of Henry Schein in a research note on Monday. Piper Sandler reduced their price objective on Henry Schein from $83.00 to $77.00 and set an “overweight” rating for the company in a research report on Wednesday, April 30th. Evercore ISI raised their price objective on Henry Schein from $72.00 to $78.00 and gave the company an “in-line” rating in a research report on Wednesday, July 9th. Finally, Wall Street Zen lowered Henry Schein from a “buy” rating to a “hold” rating in a report on Thursday, April 17th. Eight research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, Henry Schein presently has an average rating of “Hold” and a consensus price target of $78.36.
Read Our Latest Stock Analysis on Henry Schein
About Henry Schein
Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
Read More
- Five stocks we like better than Henry Schein
- How to Use High Beta Stocks to Maximize Your Investing Profits
- JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth
- Stock Market Upgrades: What Are They?
- Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook
- Insider Trading – What You Need to Know
- Fastenal Surges After Earnings Beat, Tariff Risks Loom
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.